Closed Trials
Number
Name
Indication
Administration of Her2 Chimeric Receptor and TGFbeta Dominant Negative Receptor (DNR) Expressing EBV Specific Lymphocytes for Subjects With Advanced Her2 Positive Malignancy (HERCREEM)
Advanced stage or metastatic HER2-positive cancer (Immunohistochemistry or reverse transcription-polymerase chain reaction (RT-PCR) is used to determine HER2 positivity)
Administration of Her2 Chimeric Antigen Receptor Expressing T Cells for Subjects With Advanced Sarcoma (HEROS)
Recurrent/progressive HER2-positive sarcomas
Administration of HER2 Chimeric Antigen Receptor Expressing CMV-Specific Cytotoxic T Cells Ins Patients With Glioblastoma Multiforme (HERT-GBM)
Glioblastoma multiforme
Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Malignancies
A cluster of differentiation 19 (CD19)-expressing B cell ALL or lymphoma and must have relapsed or refractory disease
Pilot Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRζ and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma (Pedi CART-19)
Patients with Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma
Pediatric Leukemia Adoptive Therapy (PLAT)-01: A Phase 1 Feasibility and Safety Study of Cellular Immunotherapy for Relapsed Pediatric CD19+ Acute Lymphoblastic Leukemia Using Autologous T-cells Lentivirally Transduced To Express a CD19-Specific Chimeric Antigen Receptor
Relapsed/refractory CD19+ acute lymphoblastic leukemia
A Phase I Trial of T Cells Expressing an anti-GD2 Chimeric Antigen Receptor in Children and Young Adults with Osteosarcoma and neuroblastoma, GD2+ Solid Tumors
Osteosarcoma and Neuroblastoma GD2+ Solid Tumors
A Phase II, single arm, multi-center trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia
Patients with Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma
Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients with Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated with Cell Therapy
Very High-Risk Subsets of B cell Acute Lymphoblastic Leukemia (B-ALL)
A Phase 1, Open Label, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3 Expressing Pediatric Cancers
Any relapsed or refractory pediatric solid tumor that shows surface expression of B7-H3
Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, Osteosarcoma and Brain Tumors
Any relapsed or refractory pediatric solid tumor that shows surface expression of B7-H3